Calcium channel blockers and Parkinson's disease: a systematic review and meta-analysis.

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-05-19 eCollection Date: 2024-01-01 DOI:10.1177/17562864241252713

Junyu Lin, Dejiang Pang, Chunyu Li, Ruwei Ou, Yujiao Yu, Yiyuan Cui, Jingxuan Huang, Huifang Shang

{"title":"Calcium channel blockers and Parkinson's disease: a systematic review and meta-analysis.","authors":"Junyu Lin, Dejiang Pang, Chunyu Li, Ruwei Ou, Yujiao Yu, Yiyuan Cui, Jingxuan Huang, Huifang Shang","doi":"10.1177/17562864241252713","DOIUrl":null,"url":null,"abstract":"Background: The calcium channel has been considered to have great potential as a drug target for neuroprotective therapy in Parkinson's disease (PD), but previous studies yielded inconsistent results.Objectives: This study aimed to conduct a systematic review and meta-analysis to assess the relationship between using calcium channel blockers (CCBs) and the risk and progression of PD.Data sources and methods: The terms such as 'Parkinson's disease', 'PD', 'calcium channel blockers', and 'CCB' were used to search the literature published before 1 May 2023 in English databases, including PubMed, Embase, and Cochrane Library, for studies on CCB and PD. Data analysis was performed using Review Manager 5.3 software.Results: A total of 190 works of literature were preliminarily retrieved, and 177 works of literature were excluded by eliminating duplicates, reading abstracts, and reading full texts. A total of nine studies were finally included in the meta-analysis of the CCB and the risk of PD, and five studies were included in the systematic review of the CCB and the progression of PD. A total of 2,961,695 participants were included in the meta-analysis. The random-effects model was used for analysis due to significant heterogeneity. The main results of the meta-analysis showed that the use of CCB could reduce the risk of PD (relative risk 0.78, 95% confidence interval 0.62-0.99).Conclusion: CCB use was associated with a significantly reduced risk of PD. Whether CCB use has a disease-modifying effect on PD needs further study.Registration: PROSPERO: CRD42024508242.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104025/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562864241252713","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The calcium channel has been considered to have great potential as a drug target for neuroprotective therapy in Parkinson's disease (PD), but previous studies yielded inconsistent results.

Objectives: This study aimed to conduct a systematic review and meta-analysis to assess the relationship between using calcium channel blockers (CCBs) and the risk and progression of PD.

Data sources and methods: The terms such as 'Parkinson's disease', 'PD', 'calcium channel blockers', and 'CCB' were used to search the literature published before 1 May 2023 in English databases, including PubMed, Embase, and Cochrane Library, for studies on CCB and PD. Data analysis was performed using Review Manager 5.3 software.

Results: A total of 190 works of literature were preliminarily retrieved, and 177 works of literature were excluded by eliminating duplicates, reading abstracts, and reading full texts. A total of nine studies were finally included in the meta-analysis of the CCB and the risk of PD, and five studies were included in the systematic review of the CCB and the progression of PD. A total of 2,961,695 participants were included in the meta-analysis. The random-effects model was used for analysis due to significant heterogeneity. The main results of the meta-analysis showed that the use of CCB could reduce the risk of PD (relative risk 0.78, 95% confidence interval 0.62-0.99).

Conclusion: CCB use was associated with a significantly reduced risk of PD. Whether CCB use has a disease-modifying effect on PD needs further study.

Registration: PROSPERO: CRD42024508242.

查看原文本刊更多论文

钙通道阻滞剂与帕金森病：系统回顾与荟萃分析。

背景：钙通道被认为是帕金森病（PD）神经保护疗法的一个极具潜力的药物靶点，但以往的研究结果并不一致：本研究旨在进行系统回顾和荟萃分析，以评估使用钙通道阻滞剂（CCBs）与帕金森病的风险和进展之间的关系：使用 "帕金森病"、"帕金森病"、"钙通道阻滞剂 "和 "CCB "等术语在PubMed、Embase和Cochrane Library等英文数据库中检索2023年5月1日前发表的有关CCB和帕金森病的研究文献。使用Review Manager 5.3软件进行数据分析：初步检索到190篇文献，通过剔除重复文献、阅读摘要和阅读全文，排除了177篇文献。最终共有9项研究被纳入CCB与帕金森病风险的荟萃分析，5项研究被纳入CCB与帕金森病进展的系统综述。共有2,961,695名参与者被纳入荟萃分析。由于存在显著的异质性，因此采用随机效应模型进行分析。荟萃分析的主要结果显示，使用CCB可降低PD的风险（相对风险为0.78，95%置信区间为0.62-0.99）：结论：CCB的使用与PD风险的显著降低有关。结论：服用氯解磷定可明显降低帕金森氏症的风险，但服用氯解磷定是否对帕金森氏症有疾病调节作用还需进一步研究：PROCROPERO：CRD42024508242。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.